Effect of NSAID Consumption on Renal Cell Carcinoma Prognosis: A Population-Based Study

This study examines the impact of NSAID consumption on renal cell carcinoma (RCC) prognosis using a retrospective cohort of 7,492 patients diagnosed between 1995 and 2015. Multivariate analyses revealed a slight increase in RCC mortality among NSAID users, particularly among women. The findings highlight the need for further investigation into gender-specific effects of NSAID use on RCC outcomes. Objective: The objective is to study the effect of NSAID consumption on renal cell carcinoma prognosis. Methods: In retrospective cohort study patients diagnosed with renal cell carcinoma (RCC) between 1995 and 2015 ( n = 7492) were divided into subgroups based on their NSAID use. Multivariate adjusted analyses were performed using cox's regression model to evaluate hazard ratio for RCC mortality. Analyses were conducted separately for acetylsalicylic acid (ASA), COX-2 selective inhibitor (COXIB), and NSAID (including ASA and COXIB) users. Results: Any NSAID consumption prior to the diagnosis of RCC exhibits a slightly elevated mortality rate compared to individuals who do not consume NSAIDs (HR 1.08, 95% CI1.00-1.16). Pre- and postdiagnostic ASA and KOKSIB use, as well as postdiagnostic NSAID, ASA, and COXIB use, weren't associated with RCC mortality. Among women, NSAID use elevated RCC mortality both prior to the diagnosis (HR 1.21, 95% CI1.08-1.36, P = .005) and after the diagnosis (HR 1.15, 95% CI1.05-1.29, P = .046). Conclusion: Prediagnostic NSAID consumption slightly elevated RCC mortality. Among women, both pre- and postdiagnostic NSAID use is associated with heightened RCC mortality.